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ABSTRACT 
Background Bipolar disorder (BD) costs the English economy an estimated £5.2billion/year, largely 
through incomplete recovery. This analysis estimated the cost-effectiveness of group 
psychoeducation (PEd), versus group peer support (PS), for treating BD.  
Methods A 96-week pragmatic randomised controlled trial (RCT), conducted in NHS primary care. 
The primary analysis compared PEd with PS, using multiple imputed datasets for missing values. An 
economic model was used to compare PEd with treatment as usual (TAU). The perspective was 
Health and Personal Social Services. 
Results Participants receiving PEd (n=153) used more (costly) health-related resources than PS 
(n=151) (net cost per person £1098 (95% CI, £252-£1943)), with a quality-adjusted life year (QALY) 
gain of 0.023 (95% CI, 0.001-0.056). The cost per QALY gained was £47,739. PEd may be cost-
effective (versus PS) if decision makers are willing to pay at least £37,500 per QALY gained. PEd costs 
£10,765 more than PS to avoid one relapse. The economic model indicates that PEd may be cost-
effective versus TAU if it reduces the probability of relapse (by 15%) or reduces the probability of 
and increases time to relapse (by 10%). 
Limitations Participants were generally inconsistent in attending treatment sessions and low 
numbers had complete cost/QALY data. Factors contributing to pervasive uncertainty of the results 
are discussed. 
Conclusions This is the first economic evaluation of PEd versus PS in a pragmatic trial. PEd is 
associated with a modest improvement in health status and higher costs than PS. There is a high 
level of uncertainty in the data and results. 
 
Keywords: cost-effectiveness; bipolar disorder; psychoeducation; peer support 
 
Highlights:  
 The cost-effectiveness of group psychoeducation (PEd) to treat BD is unknown 
 Data were collected as part of a pragmatic randomised controlled trial (RCT) 
 The control treatment in the RCT was group peer support (PS) 
 PEd may be cost-effective but this is uncertain 
 Further economic data may help to address this uncertainty 
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1. INTRODUCTION 
Bipolar disorder (BD) is the 18th leading cause of disability (years lived with) for any health problem 
(1). BD has been estimated to cost the English economy £5.2 billion annually, largely due to 
incomplete recovery as a result of inadequate treatment(2).  
 
Traditionally, medications such as lithium carbonate have been used to prevent episodes of illness 
and are still recommended for this purpose(3) but are only partially effective. In high income 
countries people with BD often have the opportunity to access peer support (PS) groups, in addition 
to medication and support from health professionals. People with BD value such support (4) which 
may improve self-efficacy and be effective in managing many long term health conditions (5). Clinical 
guidelines for the management of BD recommend psychological treatment for the prevention of 
relapse in addition to pharmacotherapy (6;7). Current guidelines for England recommend 
manualised evidence-based psychological interventions developed specifically for BD as a 
component of long-term management of BD (3).  
 
Because relatively large groups (10 to 18 people) can undertake treatment together, manualised 
psychological interventions delivered to groups, for example group psychoeducation (PEd), may be 
an efficient option for mental health services to improve outcomes for people with BD. Although 
therapists need to be trained to run the groups, the intervention is highly manualised and training is 
less intensive than for other psychological approaches such as individual cognitive behavioural 
therapy (CBT)(8). The existing evidence base for group psychological treatments in preventing 
relapses for BD is inconsistent. The first trial of PEd in a group of people with BD, showed clinical and 
cost-effectiveness for all types of bipolar relapse(9-11). Generally however findings from previous 
trials of PEd have been heterogeneous in design, often involving a small number of participants and 
short follow-up periods. They reported inconsistent effects on mood symptoms, quality of life, or 
functioning (12).  
 
The analyses described here were part of an integrated clinical and economic randomised controlled 
trial (RCT) of the effectiveness of PEd compared to PS (trial acronym: PARADES) (13). Results 
suggested that while PEd was no more clinically effective than PS it was more acceptable to 
participants. PS, rather than treatment as usual (TAU), was chosen as the comparator in the RCT as 
the clinical aim was to compare PEd with an unstructured group-based intervention, matching for 
attentional effects. However, PS is not standard care in the UK, opportunities to access PS are highly 
variable, and to our knowledge there is no plan to establish PS in clinical practice. Furthermore a key 
problem identified in the National Institute for Health and Care Excellence (NICE) guideline for 
bipolar disorder (CG185) was that there was insufficient evidence to model the relative cost-
effectiveness of psychological therapies compared to TAU (3). This is important because the decision 
problem facing providers is whether or not to provide PEd in addition to TAU, rather than which 
intervention to provide between PEd and PS. In order to address this, a simple economic model and 
threshold analysis were used to synthesise results of the RCT with clinical literature. This approach 
provides additional information for settings or patient groups where access to psychological 
therapies such as that provided by PS is limited (13). 
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1.1 Aims and objectives The overall aim of the economic evaluation was to explore the likelihood 
that PEd is cost-effective. Specific objectives were to:  
 Estimate and compare the costs and quality-adjusted life years (QALYs) for participants in the 
intervention (PEd) and control (PS) groups at baseline and follow-up; 
 Use RCT data to assess whether there were differences in the relative cost-effectiveness of PEd 
compared with PS; 
 As PS is unlikely to be adopted as routine practice, explore whether PEd could be cost-effective 
compared with TAU, using a probabilistic simulation (economic) model. 
 
2. METHODS  
The design and results of the PARADES RCT have been described in detail elsewhere (14;15). Key 
features of the trial are described in brief here. 
 
2.1 Population The target population was people with bipolar 1 or 2 affective disorder, not currently 
in episode but at increased risk of further relapse (defined as having had at least one episode in the 
last 24 months). The mean age of the sample was 45 years and 42% were male. Detailed 
characteristics of the trial sample are reported alongside the clinical results of the trial (14). The 
recruitment strategy was deliberately broad to ensure that the sample reflected a diversity of people 
with BD.  
 
2.2 Intervention A detailed description of the interventions has been published as part of the clinical 
evaluation(14). A dual-region, single-blind, RCT compared the effectiveness of:  
 21 weekly bipolar group PEd sessions delivered by two health professionals (nurse, 
psychiatrist, psychologist or occupational therapist) and a service-user (SU) facilitator, plus 
TAU. 
 21 weekly unstructured bipolar group PS sessions delivered by two health professionals and 
a 'service-user' facilitator, plus TAU(15). 
 
Both treatments were delivered over a period of up to 26 weeks (allowing for holiday periods) (15). 
As part of PEd, a manual covering the 21 sessions was produced, with a session-specific handout for 
each session and opportunities for further 'homework tasks'. For PS, a short manual outlining group 
rules was used and participants collectively decided upon an agenda for discussion at each session. 
Both interventions were delivered adjunctively to treatment prescribed by their usual physician.  
Consecutively eligible people were individually randomised to either treatment, with minimisation 
by number of previous bipolar episodes (1-7, 8-19, 20+), and stratification by clinical site. 
Participants in both arms were followed-up over 96 weeks to allow sufficient time to observe 
changes in primary and secondary outcomes, while being feasible to implement. 
 
2.3 Outcomes The primary measure of health benefit was the quality-adjusted life year (QALY). This 
was calculated based on participants' responses on the EQ-5D (3-level version) questionnaire and 
the published tariff of associated utility values for the UK (Measurement and Valuation of 
Health A1 tariff) (16;17). Participants were asked to complete the EQ-5D at the scheduled baseline, 
32, 64 and 96 weeks assessments. QALYs were estimated in line with NICE recommendations for 
economics evaluations (18).  
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The EQ-5D has been shown to correlate with primary clinical outcome measures in previous trials of 
psychosis(19;20) and BD(21). Furthermore baseline utility values derived from the EQ-5D for the RCT 
sample were well correlated with clinical outcome measures (HADS-anxiety: Pearson coefficient= -
0.474, p=0.000; HADS-depression: Pearson coefficient= -0.481, p=0.000; n=245; whether the 
participant relapsed: Pearson coefficient =-0.234, P = 0.048).  
 
A secondary measure of health benefit was time to next bipolar episode, measured using 16-weekly 
Structured Clinical Interview for DSM-IV (SCID)-Longitudinal Interval Follow-up Evaluation (LIFE) 
interviews (22) to generate scores of mania and depression (23;24), or clinical notes where available.  
 
2.4 Measuring costs The costs of the PEd and PS interventions included the costs of training staff 
and service-users to deliver the intervention (trainer and trainee time), the costs of delivering the 
intervention (time of staff and service users (SUs) to run the group sessions, plus materials), and the 
costs of supervision (time of supervisors and supervisees). The resources required to deliver the 
interventions were calculated based on their description as per the trial protocol (15). The amount 
of time dedicated to training and supervisions were recorded by the individuals who delivered the 
training and supervisions. The costs per unit of time were estimated by role (e.g. Psychiatrist, 
Therapist) from published NHS reference costs (25). The cost per group was calculated by dividing 
the total cost by the number of groups run. The cost per participant was calculated by dividing the 
cost per group by the actual number of participants allocated to the group. This approach assumes 
that there are no savings associated with participants who did not attend one or more of the 
planned group sessions. The difference in cost between the PEd and PS interventions equated to the 
cost of reproducing the PEd manual given to participants. 
 
Costs associated with healthcare resource use were also considered in this analysis. These included 
the costs of the following: inpatient psychiatric and non-psychiatric care (including intensive care, 
emergency and crisis admissions); hospital outpatient and day hospital attendances; primary care 
contacts with the GP and GP practice staff; prescription medicines; community mental health care 
contacts; social care contacts. Participants were asked to report resource use at the baseline, 32, 64 
and 96 weeks assessments. Resource use data are collected using and economic patient 
questionnaire (EPQ) which includes questions from the Client Service Receipt Inventory (CSRI) (26) 
interview and service use questionnaires used in previous mental health trials (27). At each 
assessment, participants were asked to recall their use of health and social care services since the 
previous scheduled assessment (or 6-months before baseline). The direct costs were estimated from 
this resource use data combined with the most recent published national unit costs available at the 
time of data analysis. These were the Department of Health Reference costs (28), the Unit costs of 
Health and Social Care produced by the Personal Social Services Research Unit, University of Kent 
(25), and the British National Formulary for the price year 2012-13. Each item of healthcare service 
use was assigned a cost by multiplying the quantity of service used with the average unit cost for 
that item. The ranges of unit costs of the different types of health and social care services used to 
calculate the costs of health and social care used by trial participants are reported in supplementary 
material (Table S1).  
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2.5 Missing data Multiple imputation (MI) was used to derive values based on all available data for a 
particular participant for the primary analysis of both costs and QALYs. MI of both costs and QALYs is 
increasingly recognised as an appropriate approach to deal with missing observation and missing 
follow-up data(29). All missing cost and utility data were treated as missing at random. Missing 
values were imputed for each time point, rather than as total values covering the whole follow up 
period. Costs were imputed by category and utility by individual EQ-5D domain, rather than as totals. 
This was so that all available data were used to inform the imputed values. For example, participants 
may have only been missing data relating to a single category of healthcare use, and so imputation 
was used to fill in the blanks. All available cost and outcome data for a particular participant was 
used to impute missing data. The imputations were conducted in STATA version 13, using predictive 
mean matching and sequential chained equations. The variables included in the models were 
selected on the basis of potential predictive ability identified from descriptive and regression 
analyses of the pooled baseline and follow up data (29).  
 
The following variables were included in the imputation models: age; gender; whether or not the 
participant had undertaken further or higher education; whether the participant was currently in 
employment or not; whether the participant was white British or not; whether the participant was 
married or not; whether the participant lived alone or not; number of previous bipolar episodes; 
type of bipolar diagnosis; treatment allocation (PEd vs. PS); treatment group and wave; number of 
group sessions attended; last assessment attended; relapse (yes/no); time to relapse.  
 
Participants with missing data at all time points were excluded from the imputation and subsequent 
analyses. Missing total cost values (incurred during the 96-week follow-up period) were estimated 
passively from the imputed costs at each follow-up assessment, missing utility values were 
estimated passively from imputed values for each EQ-5D item. 
 
2.6 Approach The economic evaluation considered costs and outcomes incurred/received by health 
and social care agencies and patients; these are the key components of the NICE preferred Health 
and Personal Social Services (PSS) perspective (25). The setting was primary care in England. The 
time horizon was 96 weeks which reflects the need for longer term follow-up to identify relapse and 
recovery. As the time frame for the study was less than 2 full years, future costs and outcomes were 
not discounted (30). 
 
To help decision-makers compare competing interventions, the results of cost-effectiveness analyses 
are reported as a ratio of how cost-effective one intervention is compared to another. This ratio 
summarises both how much more (or less) health benefit an intervention provides and how much 
more (or less) it costs and indicates the cost to gain an additional unit of benefit beyond that gained 
from the comparator. The primary measure for this economic analysis was the incremental cost-
effectiveness ratio (ICER), estimated as: 
 
CostPEd - CostPS 
QALYPEd - QALYPS 
 
As the primary measure of the economic analysis (ICER) is a ratio, rather than a point estimate cost-
effectiveness acceptability analysis was used to assess the level of uncertainty in the data. Net costs 
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(CostPEd - CostPS) and net QALYs (QALYPEd - QALYPS) were each derived using an ordinary least squares 
(OLS) regression model with total cost/utility as the dependent variable and treatment allocation as 
the independent variable. The primary analysis was adjusted for baseline characteristics of the 
sample.   
 
2.6.1 Within-trial analysis For the PEd versus PS data evaluation the estimates of incremental costs 
and outcomes from the regression were bootstrapped to simulate 10,000 pairs of net cost and net 
outcomes. These simulations were used to estimate the probability that the PEd intervention is cost-
effective compared with PS and to generate cost-effectiveness acceptability curves (CEACs). CEACs 
graphically depict the level of uncertainty around the results and show the probability that PEd is the 
more cost-effective option compared to PS at different levels of willingness to pay for each QALY 
gained (within the 10,000 bootstrapped net cost and QALY pairs). This takes a Bayesian approach to 
estimating the likelihood that the intervention is cost-effective and avoids hypothesis-testing and 
risk of a Type II error. In line with this approach no statistical tests of differences in mean costs or 
outcomes were conducted, although 95% confidence intervals around the differences are presented. 
 
2.6.2 Model-based analysis For the economic model comparing PEd with TAU, Monte Carlo 
simulation (10,000 iterations) using TreeAge software was used to estimate the net costs, QALYs and 
ICER. Probabilistic sensitivity analysis was used to estimate the likelihood that PEd was cost-effective 
compared with TAU and generate cost-effectiveness acceptability curves. This required that all 
parameters were entered into the model as distributions. Beta distributions for integers were used 
for the probability data. Gamma distributions were used for the cost, utility and time data. The cost 
and time distributions were constrained to a minimum value of zero.  
 
2.7 Within trial analysis The within-trial analysis used an intent to treat approach and included all 
participants randomised to start therapy in both trial groups. Net costs and QALYs used to calculate 
the ICER for the primary economic analysis were derived using OLS regression to adjust for the 
baseline covariates identified as potential predictors of future costs and outcomes:: gender and age; 
study wave; number of previous episodes of BD; type of bipolar diagnosis (1 or 2); HADS-anxiety and 
HADS-depression scores; ethnicity (white British or not); employment status (working or not); level 
of education (further/higher education or not); living situation (living alone or not). These variables 
were used as covariates for all the primary and secondary analyses of costs, QALYs and cost-
effectiveness. In addition, the baseline SF-6D utility score and EQ-5D visual analogue scale (VAS) 
score were used as covariates in the analyses of QALY data and baseline costs were used in the 
analyses of cost data. 
 
Sensitivity analyses were used to assess the impact of uncertainty and the robustness of the results 
to changes in the measure of health benefit (time to bipolar episode) and missing data approach (MI 
versus complete case analysis). Sub-group analyses explored (rather than tested) whether the cost-
effectiveness of PEd might vary according to the characteristics identified from clinical and 
qualitative analyses (as well as descriptive economic analyses) as potentially having an impact on 
costs or benefits associated with PEd or PS: the type of BD (I or II), number of (PEd/PS) sessions 
attended, and whether the participant completed the 96-week SCID assessment.  
 
2.8 Decision tree and probabilistic simulation model A simple economic model that combined an 
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initial decision tree and a Markov model was constructed (Figure 1) to compare PEd to TAU (as 
opposed to PS). The initial decision tree structure was based on the care pathways used in the trial 
design and incorporates the distribution of participants by number of group sessions attended. 
Decision trees are simple and transparent, clarifying the options of interest. The Markov section of 
the model represents likelihood and time to first relapse following treatment, to reflect the primary 
objective of the PEd intervention. Markov models handle both costs and outcomes intuitively which 
makes them a powerful tool in economic evaluation (31). They are particularly useful for modelling 
chronic conditions with fluctuating severity, such as depression, over time. The time horizon was 96 
weeks, split into three cycles of 32 weeks.  
 
The target population for the economic model was people with bipolar 1 or 2 disorder at increased 
risk of further relapse (an episode in the last 24 months). Data from the trial sample of participants 
were used to represent this population.  
 
2.8.1 Parameter estimation Parameters used in the model are summarised in Table 2. The following 
data were observed during the RCT for participants randomised to receive PEd: probability of 
attending group sessions; probability of first relapse in the follow-up period; costs of PEd; cost per 
week of relapse/no relapse, estimated as the average cost per assessment divided by 32 weeks (time 
between assessments); the average utility associated with relapse/no relapse; time to relapse and 
time following relapse. 
 
It was assumed that the cost per week of relapse/no relapse, the utility associated with the relapse 
and no relapse states would be the same for both PEd and TAU. The probability of relapse and time 
to relapse for PEd (10-25%) were varied systematically around the values observed for PEd in the 
clinical analysis (14) to determine how effective PEd would have to be at delaying/preventing 
relapse, compared to TAU, to be cost effective (threshold analysis). The utility and cost parameters 
for the relapse and no relapse states were estimated from the multiple imputation data generated 
for the economic evaluation. 
 
3. Results 
The demographic characteristics of the sample are reported in full alongside the clinical 
effectiveness results (14).  In summary, the mean age of the sample was 45 years, 58% were female, 
91% were of white ethnicity, 80% had Type 1 BD, and over 50% had had 20+ previous bipolar 
episodes. 153 participants were randomised to receive PEd and 151 participants to receive PS.  
 
A breakdown of the intervention costs by wave and study centre is presented in supplementary 
material (Table S2). Training, session delivery, and supervision costs were equivalent for PEd and PS, 
(total for each of PEd and PS - training: £14,896, sessions: £51,282, supervision: £2,080). PEd was 
more expensive than PS because of the in-depth manuals distributed to PEd participants (total cost 
£616). The total cost to deliver 21 sessions (one wave) of PS was £6,206 and £6,261 for PEd 
(calculated by dividing the total intervention cost by the number of waves (i.e. 11)). . The 
intervention design was such that the cost to deliver  each wave of sessions were incurred whether 
or not all participants attended all sessions. The estimated intervention cost per participant was 
calculated by dividing the cost per wave by the average number of planned participants per wave. 
The mean number of planned participants per wave was 14 and so the cost per participant was 
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estimated as the mean cost to deliver 21 sessions divided by the planned group size i.e. 
£6261/14=£447 for PEd and £6206/14=£443 for PS. Given the similar costs of the two interventions, 
additional costs incurred in the PEd participants indicates higher use of health and social care 
services. Mean values for the main categories of healthcare costs and utility for PEd and PS are 
reported in supplementary material (Table S3). 
 
The pattern of available cost and utility data across the different assessments are summarised in 
Table S4. The proportion of the sample that it was possible to calculate costs or utilities for was 91% 
and 85% at baseline and decreased at each subsequent assessment. The proportion of the sample 
with at least partial data recorded for resource use or utilities was marginally higher at baseline, 98% 
and 88% respectively. At the final assessment (week 96) 57% had full data recorded for resource use 
and 33% had full EQ-5D data allowing estimation of a utility value. Additionally, 65% (PS) and 71% 
(PEd) participants had partial data about service use at the final assessment.  Over half the sample 
(54%) had both resource use and utility data at 2 or more time points and a third (34%) had these 
data at 3 or 4 time points. Around a quarter (23%) of the sample had resource use and utility data at 
both baseline and final assessment. Overall, cost data were more complete than utility data with 
similar proportions of available data for PEd and PS participants. 
 
3.1 PEd versus PS (within-trial analysis) Table 1 reports net costs and QALYS, estimated from 
regression analysis of imputed data (after controlling for the effect of baseline characteristics, trial 
implementation, and treating costs and QALYs as independent of each other). There was a small 
QALY gain of 0.023 (95% CI, 0.001-0.056 associated with the PEd intervention and an additional cost 
(healthcare resources used) of £1098 (95% CI, £252-£1943). The point estimate of the net cost per 
QALY gained is relatively high at £47,739 (£1098/0.023 QALY), which is above the commonly 
reported NICE threshold of £20,000 to £30,000 per QALY gained (18). There is some uncertainty 
associated with this cost per QALY estimate. This uncertainty is illustrated in Figure 2 (panel a), 
which presents a scatterplot of the 10,000 bootstrapped pairs of net cost and QALY data (cost-
effectiveness plane). The cost-effectiveness plane shows that the net costs are mostly scattered 
above the horizontal axis, suggesting that overall PEd is likely to cost more than PS. The net QALY 
points on the scatterplot are mainly to the right of the vertical axis, suggesting that PEd is more likely 
than PS to produce a health benefit. The uncertainty is also reflected in the probability that PEd is 
more cost-effective than PS (Table 1). The cost-effectiveness acceptability curve (CEAC) presented in 
Figure 2 (panel b) illustrates that compared with PS, the PEd intervention is likely to be cost-effective 
in 50% or more cases if decision-makers are willing to pay £37,500 or more to gain one QALY. This 
value is a measure of the uncertainty around the ICER, commonly reported in cost-effectiveness 
evaluations, and is akin to reporting a 95% CI alongside a point estimate.  
 
3.1.1 PEd versus PS: Sensitivity and sub-group analyses PEd is more likely to be cost-effective than 
PS in the following scenarios (Table 1): complete case analysis (no multiple imputation of missing 
data); over 64 weeks (rather than 96 weeks); alternative measures of health benefit (relapse 
avoided; relapse free years). Sub-group analysis exploring the impact of Type of bipolar diagnosis 
indicates that PEd was more likely to be cost effective compared to PS in participants with a Type 2 
bipolar diagnosis. PS dominates PEd (lower costs and higher QALYs for PS) in the following scenarios: 
fewer than 8 previous bipolar episodes; fewer than 16 group sessions attended; when participants 
did not complete SCID at 96-week assessment. It is important to note that these analyses are 
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exploratory and the sample size available for each analysis may not be sufficient to identify 
important differences. The cost-effectiveness acceptability curves for selected sensitivity and sub-
group analyses are summarised in Figure 2 (panels c and d). The full results for all sensitivity and sub-
group analyses conducted are reported in supplementary material (Tables S5-6).  
 
3.2 PEd versus TAU (model-based analysis) Table 2 summarises the decision tree events and 
structure and describes the probability data inputs to the economic model and the cost, utility and 
time data used, derived from the within-trial analyses. 
 
The net costs and QALYs of PEd compared with TAU are shown in Table 3, while Figure 3 gives the 
cost-effectiveness acceptability curves for the analyses. The analyses demonstrate that if PEd 
reduces the probability that a person has a relapse by 15% (regardless of time to relapse) compared 
to TAU, then the net cost to gain one QALY from PEd (£9700) falls well below the £30,000 threshold.  
If the probability of relapse is 25% higher in TAU than PEd, then PEd dominates TAU (lower costs, 
higher QALYs for PEd). A systematic review (12) indicated that for TAU, the probability of relapse 
over an average of 60 weeks is 0.70. At 60 weeks, the probability of relapse observed for the PEd 
participants in our study was 0.50 i.e. probability of relapse is 20% higher for TAU.  
 
The clinical analysis showed that the median time from baseline to next bipolar episode was 67 
weeks (95% CI 37–91) in the psychoeducation group versus 48 weeks (95% CI 31–66) in the peer-
support group (14). Results from the economic model suggest that if PEd reduces the probability 
that a person has a relapse by 10% and increases the time to relapse by 10% compared to TAU, then 
the net cost to gain one QALY (£10,300) is again lower than £30,000. If the probability of relapse is 
15% higher and time to relapse is 15% lower in TAU than PEd, then PEd dominates TAU (lower costs, 
higher QALYs for PEd).  The average time to relapse observed in our study was around 30 weeks 
(95% CI, 24-35) for PEd. Previous studies suggest that the average time to relapse under TAU is 
around 20 weeks (12) (i.e. 33% sooner).  
 
Even though the ICERs reported in Table 3 are below £20,000, the estimated probability that PEd is 
cost-effective compared to TAU if decision-makers are willing to pay £20,000 or even £30,000 are 
not much higher than chance (0.50).  This reflects the uncertainty around the ICERs. 
 
4. DISCUSSION 
Primary analysis suggested a net additional cost for the PEd intervention and a small QALY gain 
compared to the active PS control intervention. There is a 35% probability that PEd is cost-effective, 
compared to PS if decision makers are willing to pay £30,000 to gain one QALY. The PEd 
intervention, compared with PS, was only likely to be cost-effective if decision-makers are willing to 
pay at least £37,500 to gain one QALY. The incremental cost to gain one relapse-free year was £8382 
and to avoid one relapse was £10,765. Decision-makers must be prepared to pay at least these 
amounts for the respective outcomes for PEd to be potentially more cost-effective than PS.  
However PS of the intensity used for the control arm in this trial is not available in routine care and 
so comparison with TAU may be more meaningful for decision-makers.  
 
The results of the economic model suggest that if PEd is more effective at reducing the probability of 
relapse or delaying relapse compared with TAU then PEd could potentially be cost-effective. The 
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difference in effectiveness of PEd and TAU required for PEd to be cost-effective is smaller than the 
difference in relapse times/rates observed in our study (PEd) and those reported in a systematic 
review (TAU) (12). However the economic model analyses indicated that the 95% CIs for the net 
costs and QALYs were wide and included zero, indicating a high level of uncertainty around these 
estimates. 
 
The higher costs observed for participants in the PEd group arose from healthcare services used, 
rather than the intervention (which cost £4 per participant more than PS). One element of PEd 
encouraged appropriate use of healthcare services which may explain this observation. However 
healthcare utilisation did not show any clear pattern over the 96 week follow-up to support or 
contradict this. Evaluation of healthcare utilisation over a longer time period following PEd may offer 
further explanation. 
 
4.1 Strengths and limitations The within-trial economic analysis was subject to the same strengths 
and limitations as described in detail for the clinical evaluation of PEd (14). In brief, there was high 
retention during follow-up, good internal and external validity, inconsistent attendance at treatment 
groups, and possible floor effects as an artefact of recruiting only participants with low levels of 
depression and mania. An additional issue that is relevant for the economic analysis is the low level 
of participants with complete cost and utility data.  
 
Although there was a high follow up rate for the primary outcome of the trial, the number of 
participants completing the secondary outcome measures (including the EQ-5D) and service use 
questionnaire was much lower, in part reflecting a focus on ensuring that the primary outcome 
measure was completed. As demonstrated in Table S4, the extent of missing data differed between 
service use and estimated costs (57% of participants had complete cost data at the week 96 
assessment) and QALYs (33% had complete 96-week data). This was due in part to partially 
completed EQ-5D and healthcare utilisation surveys. This adds uncertainty to the results of the 
primary and sensitivity analyses of the costs and outcomes. Multiple imputation was used to impute 
missing values to "fill in the blanks" while still using all available data. The regression models used to 
impute missing data were based on initial descriptive analyses and regression analyses to identify 
key baseline and follow-up variables that were associated with either costs or outcomes. These were 
included in the chained equations to iteratively impute missing cost categories and utilities. This 
goes some way to controlling for the influence of observed variables on the missing data. However, 
the influence of unobserved variables could not be taken into account, and it is unclear the extent to 
which this was important and affects the assumption that missing data were missing at random.  
 
Given the level of missing data, this number of MI datasets for the cost estimates is likely to be 98% 
efficient with a 2% loss of power. For QALY estimates, 10 MI datasets is likely to be 94% efficient 
with a 9% loss of power. Overall the efficiency of 10 MI datasets for the ICER estimates is likely to be 
lower (89%-93%) and the loss of power higher (14%) (32). Using the rule of thumb suggested by 
White et al (33), we would need 43 MI datasets for costs, 67 MI datasets for QALYs and 83 MI 
datasets to ensure that the results from the MI analyses are stable. However, the available data 
approach used would increase the computational burden substantially.   
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The economic analyses used OLS regression to take account key baseline characteristics that may 
affect costs and QALYs. In cases where clustering of data occurs (e.g. by treatment group) multi-level 
analyses may be a better approach for reliable and unbiased estimation of the cost and QALY 
coefficients and standard errors.  The primary clinical analysis found no evidence of clustering by 
therapy group.  The exploratory sub-group analyses identified possible effects that could be assessed 
in future using multi-level modelling approaches. 
 
QALYs were used as the measure of health benefit for the primary analysis and most of the 
sensitivity and sub-group analyses. This enables comparison between different disorders which is 
relevant for policy makers and commissioners, who have to consider the distribution of limited 
budgets between different health care services. However, there is a possibility that a generic health 
status measure may not be sufficiently sensitive to identify important clinical changes in 
participant’s mental health or bipolar status and so could underestimate the benefits of PEd. 
However baseline utility values derived from the EQ-5D in this sample correlated well with the 
clinical measures used in the trial.  
 
The costs included in the economic evaluation were limited to the direct costs of providing health 
and social care, in accordance with the perspective taken. This will underestimate the total costs of 
bipolar disorder for the trial participants. If there are differences in the effectiveness of the PEd or PS 
interventions that lead to differences in employment between the two groups, then this will also 
affect the net costs associated with PEd. If employment is higher in the PEd group, then the net cost 
of the PEd group will be slower than estimated, and the likelihood that PEd is cost–effective may 
increase, and vice versa.  
 
An assessment of the likely cost-effectiveness of PEd compared with TAU is important for 
commissioners and service providers. The PS intervention used as the control treatment in our study 
involved a closed group of only people with BD meeting with health professionals and a peer 
facilitator with an agenda for each session previously set by consensus by the group.  This type of 
group support is not available in UK routine care. Typically PS is delivered by peers in a open format 
with people with BD and their carers or families attending as frequently as they like and usually with 
no set agenda for each session (http://www.bipolaruk.org/Pages/Category/support-groups). 
However there was limited evidence from the published literature to inform the structure of a full 
economic model that compares PEd with TAU or estimate the costs and QALYs associated with 
events in the TAU arm of the model. The advantage of populating the modelling with data from the 
RCT in relation to PEd is that it introduces less heterogeneity and uncertainty than had data for both 
PEd and TAU been synthesised from several sources. However this also means that the scope of the 
model and relevance of the model results are constrained by the trial design and the people with BD 
recruited into the main RCT.  
 
If as seems likely, commissioners and service providers wish to focus on relapse-free years, then PEd 
is much more likely to be cost-effective than PS, with less uncertainty. Whether the NICE thresholds 
for cost per relapse-free year gained would be as high as those for cost per QALY gained is unclear  
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4.2 Implications Sensitivity and sub-group analyses were conducted to explore whether aspects of 
the trial and economic evaluation design may affect the likelihood that PEd is cost-effective. This 
approach can help to identify issues for policy and indicated a number of areas for further research. 
These analyses also explored whether there were specific groups of participants who may benefit 
more from PEd. However, it is important to note that these analyses are exploratory, and the sample 
size available for each analysis may not be sufficient to identify important differences. Additionally, 
the number of these exploratory analyses increases the chance of finding a difference between the 
exploratory analysis and the primary analysis because of the number of analyses, rather than 
because an important difference exists.  
 
The results were sensitive to the length of follow-up. PEd was more likely to be cost-effective at the 
64-week assessment than the 96-week assessment- driven by a difference in net costs (rather than 
QALYs). Further work to identify the trajectory of costs and QALYs during the intervention phase and 
over the longer term is needed. This will help to understand whether the change found in our study 
reflects what would happen is routine practice.  
 
Sub-group analysis of the economic data indicated that PEd might be cost-effective compared with 
PS for people with Type 2 BD and those who attended 16 or more sessions. The sub-group analyses 
also indicate that the number of sessions attended affected the relative cost-effectiveness of PEd. 
This highlights the need for careful identification of people who are likely to engage with and benefit 
from the intervention. Further work to understand the influence of a participants’ overall health on 
decisions to participate in PEd or PS is needed. This would help to target the intervention at 
participants able and willing to engage in the group intervention and/or improve access to group 
interventions. 
 
4.3 Conclusion In conclusion, PEd is associated with a modest improvement in health status and 
higher costs than PS.  There is a high level of uncertainty in the data and results. 
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Table 1 Net costs and QALYs of group psychoeducation (PEd) compared to group peer support (PS), multiple 
imputation data, adjusted for baseline characteristics* and bootstrapped 
 Net cost 
(95% CI) 
Net QALY  
(95% CI) 
Net cost 
per QALY 
gained 
Probability PEd cost 
effective if willing to 
pay £30K to gain 1 
QALY 
Primary analysis  £1098  
(252; 1943) 
0.023  
(0.001; 0.056) 
£47,739 
 
0.35 
Sensitivity analyses  
Type of imputation 
Complete case analysis 
(n=55) 
-£588  
(-4734; 3558) 
0.049  
(-0.177; 0.274) 
PEd 
dominates 
0.83 
Shorter length of follow up  
Baseline to 64 weeks 
(n=280) 
£698 
(209; 1187) 
0.027 
(0.006; 0.048) 
£25,852 0.63 
Alternative measures of health benefit 
 Net cost 
(95% CI) 
Net time relapse 
free (years) 
(95% CI) 
Net cost 
per relapse 
free year 
gained 
Probability PEd cost 
effective if willing to 
pay £30K to gain 1 
relapse free year 
Relapse free years (n=287) £1098  
(252; 1943) 
0.131 
(0.08; 0.182) 
£8,382 0.99  
 
 Net cost 
(95% CI) 
Net number of 
relapses avoided 
(95% CI) 
Net cost 
per relapse 
avoided 
Probability PEd cost 
effective if willing to 
pay £30K to avoid 1 
relapse 
Relapse avoided during 
follow-up (n=287) 
£1098  
(252; 1943) 
0.102 
(0.67; 137) 
£10,765 0.99 
 
Sub-group analysis 
 Net cost 
(95% CI) 
Net QALY  
(95% CI) 
Net cost 
per QALY 
gained 
Probability PEd cost 
effective if willing to 
pay £30K to gain 1 
QALY 
Participants with Type 2 
bipolar diagnosis (n=58) 
£375 
(-107; 857) 
0.129 
(0.077; 0.181) 
£2907 1.00 
0-15 PEd or PS sessions 
attended (n=169) 
£955 
(332; 1577) 
-0.003 
(-0.040; 0.043) 
PS 
dominates 
0.07 
16+ PEd or PS sessions 
attended (n=118) 
-£844 
(-1997; 308) 
0.080 
(0.036; 0.124) 
PEd 
dominates 
0.99 
*gender, age, study wave, number of previous episodes of BD, type of bipolar diagnosis (1 or 2), HADS-anxiety 
and HADS-depression scores, ethnicity, employment status, level of education, living situation, SF-6D utility 
score, EQ-5D thermometer, pre-baseline healthcare costs 
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Table 2 Economic model parameters: probability of events, costs, utility and time to relapse 
Model branch Event sequence Probability (95 CI%) 
1  Attends at least one session 0.78 (0.71-0.74) 
1.1  Attends 2-9 sessions 0.19 (0.13-0.27) 
1.1.1  First relapse, baseline-week 32 0.61 (0.39-0.79) 
1.1.2  No first relapse, baseline-week 32 0.39 (0.21-0.61) 
1.1.2.1  First relapse, week 33-64 0.11 (0.01-0.55) 
1.1.2.2 No first relapse, week 33-64 0.89 (0.45-0.99) 
1.1.2.2.1 First relapse, week 65-96 0.13 (0.01-0.60) 
1.1.2.2.2 No first relapse, week 65-96 0.87 (0.40-0.99) 
1.2 Attends more than 9 sessions 0.81 (0.73-0.87) 
1.2.1 Attends 10-15 sessions 0.31 (0.22-0.41) 
1.2.1.1 First relapse, baseline-week 32 0.43 (0.27-0.72) 
1.2.1.2 No first relapse, baseline-week 32 0.57 (0.38-0.73) 
1.2.1.2.1 First relapse, week 33-64 0.18 (0.05-0.45) 
1.2.1.2.2 No first relapse, week 33-64 0.82 (0.55-0.95) 
1.2.1.2.2.1 First relapse, week 65-96 0.21 (0.06-0.52) 
1.2.1.2.2.2 No first relapse, week 65-96 0.79 (0.48-0.94) 
1.2.2 Attends more than 15 sessions  0.69 (0.59-0.78) 
1.2.2.1 First relapse, baseline-week 32  0.33 (0.23-0.35) 
1.2.2.2 No first relapse, baseline-week 32  0.67 (0.55-0.77) 
1.2.2.2.1 First relapse, week 33-64 0.13 (0.06-0.27) 
1.2.2.2.2 No first relapse, week 33-64  0.87 (0.73-0.94) 
1.2.2.2.2.1 First relapse, week 65-96  0.23 (0.12-0.39) 
1.2.2.2.2.2 No first relapse, week 65-96 0.77 (0.61-0.88) 
2 Attends 0 sessions, continue as control  0.22 (0.16-0.20) 
Parameter PEd 
Mean (95% CI) 
PS 
Mean (95% CI) 
All 
Mean (95% CI) 
Utility 
No relapse 0.703 (0.635-0.771)  0.669 (0.595-0.743) 0.689 (0.638-0.739) 
Relapse 0.592 (0.530-0.654)  0.588 (0.524-0.653) 0.590 (0.543-0.637) 
Cost, £ 
Intervention 450 (446-454)  452 (448-456) 451 (448-454) 
No relapse 1554 (1109-1999)  1331 (850-1811) 1458 (1117-1799) 
Relapse 3154 (2103-4205)  2736 (2035-3436) 2933 (2318-3549) 
Weeks to relapse (within cycle) 
Week 0-32 14.47 (12.11-16.82)  13.04 (11.02-15.05) 13.74 (12.20-15.28) 
Week 33-64 18.03 (12.46-23.60)  17.05 (13.69-20.41) 17.39 (14.52-20.27) 
Week 65-96 18.85 (14.14-23.56)  18.86 (13.68-24.03) 18.85 (15.44-22.26) 
Week 0-96 29.63 (24.21-35.06)  28.54 (23.76-33.32) 29.06 (25.49-32.63) 
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Table 3 Economic model: Net costs and QALYs of PEd compared with TAU 
 Net cost,  
(95% CI) 
Net QALY,  
(95% CI) 
Net cost  
per QALY, £ 
Probability PEd cost effective 
 WTPT = £20K 
per QALY 
WTPT = £25K 
per QALY 
WTPT = £30K 
per QALY 
Probability of relapse higher in TAU than PEd1 
15% higher 97  
(-6613; 4890) 
0.010 
(-0.266; 0.269) 
9700 
 
0.48 0.50 0.51 
20% higher 18 
(-7404; 5065) 
0.014 
(-0.277; 0.290) 
1286 0.50 0.51 0.52 
25% higher -60 
(-8142; 5136) 
0.017 
(-0.292; 0.312) 
PEd dominates 0.51 0.52 0.53 
Probability and time to relapse2  
Probability 10% higher, 
time 10% lower  
£103 
(-5912; 4320) 
0.010 
(-0.233; 0.240) 
£10,300 0.48 0.49 0.50 
Probability 15% higher, 
time 15% lower 
-£18 
(-6710; 4123) 
0.015 
(-0.233; 0.263) 
PEd dominates 0.50 0.51 0.52 
Probability 20% higher, 
time 20% lower 
£-141 
(-7558; 4135) 
0.020 
(-0.239; 0.288) 
PEd dominates 0.52 0.53 0.54 
1probability of relapse in PEd = 0.58 (95% CI 0.50-0.66) 
2mean time (weeks) to relapse in PEd = 29.63 (95% CI 24.21-35.06) 
WTPT = willingness to pay threshold 
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Figure 1 Economic model: decision tree and Markov model structure 
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Figure 2 (a) Cost effectiveness plane of bootstrapped net cost and QALY pairs (primary analysis); (b) cost 
effectiveness acceptability curve (primary analysis); (c) cost effectiveness acceptability curve (complete 
cases, clinical outcome measures); (d) cost effectiveness acceptability curve (length of follow-up, number of 
sessions attended, bipolar type) 
(a) 
 
(b)  
 
(c) 
 
(d) 
 
Data represented in figures are from multiple imputed datasets and have been adjusted for the 
following covariates: gender and age; study wave; number of previous episodes of BD; type of 
bipolar diagnosis (1 or 2); HADS-anxiety and HADS-depression scores; ethnicity (white British or not); 
employment status (working or not); level of education (further/higher education or not); living 
situation (living alone or not). Baseline SF-6D utility score and EQ-5D thermometer were used as 
covariates in the analyses of QALY data only and baseline costs were used in the analyses of cost 
data only. 
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Figure 3 Cost effectiveness acceptability curves, willingness to pay to gain 1 QALY, comparison with TAU: (a) 
probability of relapse; (b) time to and probability of relapse 
(a) 
 
(b) 
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Supplementary material 
Table S1 Mean (range) unit costs of health and social care services 
Service type 
 
Range of unit costs (£) 
Source 
Psychiatric hospital 
inpatient admission 
348 per day (acute psychiatric ward) 
334 per day (rehabilitation ward) 
736 per day (psychiatric intensive care ward) 
NHS Reference costs 
(28)  
Other hospital 
inpatient admission 
491 per day (general medical ward) 
1,650 per day (Ear nose and throat, day case admission) 
NHS Reference costs 
(28) 
Psychiatric hospital 
outpatient care  
221 per visit (adult mental illness) 
102-216 per visit (other psychiatric outpatient visits) 
145-191 per visit (psychotherapy, psychology) 
184 per visit (crisis team) 
24.90 per visit (depot clinic) 
NHS Reference costs 
(28) 
Other hospital 
outpatient admissions 
108 per visit (type of visit not specified, costed as average of all 
outpatient visits) 
26-215 per visit (other physical health care) 
NHS Reference costs 
(28) 
Tests and diagnostics 
3-4 per test (haematology, phlebotomy) 
28-177 per test (x-rays, scans, MRI, biopsy) 
NHS Reference costs 
(28) 
General practice   
GP 
37.50 (per surgery visit)  
 94.50 (per home visit) 
PSSRU Unit costs of 
health and social care 
(25) 
Practice nurse 
12.40 per visit 
Single estimate, no range 
PSSRU Unit costs of 
health and social care 
(25) 
District nurse, health 
visitor, midwifery 
59.58 per visit 
Single estimate, no range 
PSSRU Unit costs of 
health and social care 
(25) 
Other primary physical 
health care 
25-115 per visit 
NHS Reference costs 
(28) and PSSRU Unit 
costs of health and 
social care (25) 
Community mental 
health/social care  
13.50 per visit (Home help/Care worker/health care 
assistant/clinical or care support worker/link mental health 
worker/support time and recovery worker) 
68-135 per visit (Community Psychiatric Nurse/Case Manager, 
care coordinator/CMHT) 
58-123 per visit (counselling and therapy) 
204.50 per visit (psychiatrist) 
91-204 (other miscellaneous services) 
207 per visit (social worker) 
13.50-104 per visit (other miscellaneous services) 
NHS Reference costs 
(28) and PSSRU Unit 
costs of health and 
social care (25) 
 
  
21 
 
Table S2 Costa of the psychoeducation (PEd) and peer support (PS) interventions 
 
Wave, 
location, 
year started 
PEd PS 
Planned no. 
participants 
No. (%) 
attend 1+ 
sessions 
Cost/planned 
participant, £ 
Planned no. 
participants 
No. (%) 
attend 1+ 
sessions 
Cost/planned 
participant, £ 
Wave 1 
Manchester 
2009 
12 10 (83) 522 12 10 (83) 517 
Wave 2 
Manchester 
2010 
17  13 (76) 368 15  12 (80) 414 
Wave 3 
Barrow 2010 
10  
 
9 (90) 626 11  11 (100) 564 
Wave 4 
Carlisle 2010 
17  15 (88) 368 17  16 (94) 365 
Wave 5 
Preston 2010 
16  12 (75) 391 16  14 (88) 388 
Wave 6 
Preston 2011 
14  14 (100) 447 15  11 (73) 414 
Wave 7 
Nottingham 
2009 
14  13 (93) 447 11  11 (100) 564 
Wave 8 
Mansfield 
2010 
11  11 (100) 569 10  7 (70) 621 
Wave 9 
Boston 2010 
11  8 (73) 569 13  10 (77) 477 
Wave 10 
Chesterfield 
2011 
14  11 (79) 447 14  12 (86) 443 
Wave 11 
Nottingham 
2012 
17  17 (100) 368 17  15 (88) 365 
aCosts reported in table are rounded to nearest £ 
The cost for each wave of 21 sessions was calculated as: total intervention cost (training, delivery, supervision) 
for treatment type/number of waves (i.e. 11) 
The cost per planned participant was calculated as: wave cost/number of planned participants 
Mean intervention cost per participant was calculated as: cost per planned participant*mean number of 
planned participants (i.e. 14) 
Unit costs for facilitators/trainers (derived from PSSRU Unit Costs of Health and Social Care were: Consultant 
Psychiatrist, £101/hour; Clinical Psychologist, £59/hour; Trainee Psychiatrist, £56/hour; Therapist, £42/hour; 
Service user, £13/hour.  
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Table S3 Mean utility values and costs of healthcare services used by treatment group (imputed 
data)  
 PEd (n = 153) PS (n = 151) 
EQ-5D Utility values Mean (95%CI) Mean (95%CI) 
Baseline 0.69 (0.64- 0.74) n=133 0.68 (0.63-0.73) n=125 
32-week assessment 0.70 (0.64-0.77) n=75 0.63 (0.57-0.70) n=86 
64-week assessment 0.66 (0.59-0.74) n=66 0.62 (0.53-0.71) n=60 
96-week assessment 0.63 (0.53-0.72) n=49 0.70 (0.64-0.77) n=50 
Services used Mean cost (95%CI), £  Mean cost (95%CI), £  
6 months prior to baseline  
Hospital inpatient admission 1861 (842-2880)  n=149 2233 (935-3531) n=144 
Hospital outpatient care  609 (521-697)  n=150 613 (486-739) n=144 
General practicea 180 (138-222)  n=152 168 (129-208) n=145 
Other primary physical health care  58 (37-79) n=152 48 (27-68) n=144 
Community mental health/social care  379 (228-530) n=148 416 (254-577) n=143 
Prescription medications 461 (321-600) n=148 280 (198-363) n=144 
Baseline to week 32   
Hospital inpatient admission 981 (136-1526) n=121 671 (226-1116) n=112 
Hospital outpatient care  481 (391-571) n=121 502 (399-606) n=112 
General practicea 187 (115-259) n=121 199 (118-280) n=112 
Other primary physical health care  39 (18-60) n=121 25 (11-38) n=112 
Community mental health/social care  364 (220-509) n=121 249 (143-355) n=111 
Prescription medications 538 (375-701) n=113 360 (268-452) n=105 
Week 32 to week 64    
Hospital inpatient admission 911 (0-2033) n=108 1120 (132-2017) n=100 
Hospital outpatient care  370 (293-447) n=108 431 (338-523) n=100 
General practicea 159 (118-200) n=108 134 (97-170) n=100 
Other primary physical health care  14 (1-26) n=107 33 (11-56) n=100 
Community mental health/social care  363 (176-550) n=108 295 (162-428) n=100 
Prescription medications 504 (331-677) n=97 361 (260-461) n=88 
Week 64 to week 96    
Hospital inpatient admission 1360 (23-2697) n=107 1386 (439-2332) n=95 
Hospital outpatient care  352 (268-436) n=107 387 (291-483) n=95 
General practicea 95 (78-111) n=107 125 (92-159) n=95 
Other primary physical health care  15 (5-25) n=107 33 (4-62) n=95 
Community mental health/social care  470 (276-664) n=107 343 (91-594) n=95 
Prescription medications 652 (426-878)  n=92 431 (327-535) n=84 
bGP, practice nurse, district nurse 
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Table S4 Summary of available cost and utility data at different assessments 
 PEd n (%)  
[% partial data]a 
PS n (%)  
[% partial data]a 
Both treatment 
arms (%)  
 Cost  Utility  Cost  Utility  Cost  Utility  
Study time point 
Baseline 
142 (93) [99] 133 (87) [88] 135 (89) [98] 125 (83) [88] 91% 85% 
Week 32 
112 (73) [80] 75 (49) [49] 100 (66) [77] 86 (57) [57] 70% 53% 
Week 64 
96 (63) [71] 66 (43) [44] 85 (56) [68] 60 (40) [40] 60% 41% 
Week 96 
91 (59) [71] 49 (32) [33] 82 (54) [65] 50 (33) [34] 57% 33% 
Number of assessments with complete cost and utility data 
 PEd n (%) PS n (%) Both treatment 
arms (%) 
0 23 (15) 23 (15) 15% 
1 41 (27) 52 (35) 31% 
2 37 (24) 26 (17) 21% 
2+ 89 (58) 76 (50) 54% 
3 25 (16) 26 (17) 17% 
3+ 52 (34) 50 (33) 34% 
4 27 (18) 24 (16) 17% 
baseline and 
wk 96 39 (25) 31 (21) 23% 
aResponse to at least one domain on EQ-5D and cost for at least one category of resource use 
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Table S5 Net costs and QALYs of PEd compared to PS, sensitivity analyses, bootstrapped data, 
adjusted for baseline characteristics 
Sensitivity analysis Net cost, £  
(95% CI) 
Net QALY, 
(95% CI) 
Net cost per 
QALY gained, £ 
Probability PEd 
cost-effective If 
willing to pay 
£30K to gain one 
QALY* 
Primary analysis 1098  
(252 to 1943) 
0.023 
(0.001 to 0.056) 
47 739 0.35 
Type of imputation 
Complete case analysis 
(n = 55) 
-588  
(-4734 to 3558) 
0.049  
(-0.177 to 0.274) 
PEd dominates, 
QALY gain, net 
saving 
0.83 
Missing QALY data 
imputed by linear 
interpolation (n = 287) 
1122  
(272-1971) 
0.024  
(0.004-0.045) 
46 750 0.23 
Alternative measures of health benefit 
Relapse free years  
(n = 287) 
1098  
(252-1943) 
0.131 
(0.08-0.182) 
8382 Probability PEd 
cost-effective if 
willing to pay 
£30K to gain one 
relapse-free year: 
0.99  
Relapse avoided  
(n = 287) 
1098  
(252-1943) 
0.102 
(0.68-136) 
10 765 Probability PEd 
cost-effective if 
willing to pay 
£30K to avoid one 
relapse: 0.99 
QALY estimated from 
SF6D utility values  
(n = 287) 
1098  
(252-1943) 
0.013  
(0.000-0.027) 
84 461 
 
0.07 
Alternative cost measures 
Costs medications, 
exclude costs ‘other’ 
medicines (n = 289) 
1008  
(162-1854) 
0.028  
(0.001-0.056) 
25 200 0.41 
Costs exclude costs of 
PEd/PS (n = 287) 
1124  
(275-1974) 
0.028  
(0.001-0.056) 
40 142 0.34 
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Table S6 Net costs and QALYs of PEd compared to PS, sub-group analyses, bootstrapped data, 
adjusted for baseline characteristics 
Sub-group analysis Net cost, £ 
(95% CI) 
Net QALY, 
(95% CI) 
Net cost per QALY 
gained,  
£ 
Probability PEd cost-
effective 
(£30K/QALY gain) 
Primary analysis 1098  
(252 to 1943) 
0.023 
(0.001 to 0.056) 
47 739 0.35 
No. PEd or PS sessions attended 
<10 (n = 112) 149  
(-555 to 852) 
0.019  
(-0.025-0.064) 
7842 0.72 
10+ (n = 175)  1266  
(24-2507) 
0.023  
(-0.012-0.057) 
55 043 0.25 
16+ (n = 118) -844  
(-1997 to 308) 
0.080  
(0.036-0.124) 
PEd dominates 0.99 
1-15 (n = 138) 1598 
(896-2301) 
0.001 
(-0.040-0.043) 
1 598 000 0.02 
0-15 (n = 169) 955 
(332-1577) 
-0.003 
(-0.040-0.034) 
PS dominates 0.07 
0 (n = 31) -649 
(-2114 to 814) 
0.056 
(-0.049-0.161) 
PEd dominates  0.92  
No. previous episodes 
≥8 (n = 249) 1238 
(270-2206) 
0.030 
(0.001-0.060) 
41 267 0.34 
1-7 (n = 38) 1267 
(-451 to 2985) 
-0.056 
(-0.132-0.019) 
PS dominates 0.04  
No. previous episodes, No. sessions attended 
8+ episodes, < 16 sessions 
(n = 147) 
1026 
(385-1667) 
0.012 
(-0.028-0.052) 
85 500 0.21 
8+ episodes, 16+ sessions 
(n = 103) 
-1109 
(2504-287) 
0.043 
(-0.003-0.089) 
PEd dominates 0.99 
1-7 episodes, 16+ sessions 
(n = 15) 
-713 
(-1898-472) 
0.266  
(-0.201-0.733) 
PEd dominates 0.99  
1-7 episodes, <16 sessions 
(n = 23) 
6271 
(3716-8826) 
-0.133 
(-0.221 to -0.044) 
PS dominates 0.00 
Participant completed SCID at 96-week follow-up 
SCID score (n = 212) 983 
(-25 to 1990) 
0.038 
(0.009-0.067) 
25 868 0.61 
No SCID score (n = 75) 470 
(-273 to 1213) 
-0.017 
(-0.003 to 0.049) 
PS dominates 0.18 
Type 1 or 2 bipolar diagnosis 
Type 1 (n = 229) 1183 
(177-2189) 
0.006 
(-0.025 to 0.038) 
197 167 0.009 
Type 2 (n = 58) 375 
(-107 to 857) 
0.129 
(0.077-0.181) 
2907 1.00 
 
 
 
  
26 
 
Reference List 
 
 (1)  Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. Years lived with 
disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic 
analysis for the Global Burden of Disease Study 2010. The Lancet 2013;380(9859):2163-96. 
 (2)  McCrone PR, Dhanasiri S, Patel A, Knapp M, Lawton-Smith S. Paying the price: the cost of 
mental health care in England to 2026. King's Fund; 2008. 
 (3)  National Collaborating Centre for Mental Health, National Institute for Clinical Excellence. 
Bipolar disorder: The NICE guideline on the assessment and management of bipolar 
disorder in adults, children, and young people in primary and secondary care - CG185.  
National Institute for Clinical Excellence; 2014.  
 (4)  Morselli PL, Elgie R, Cesana BM. GAMIANEurope/BEAM survey II: crossnational analysis 
of unemployment, family history, treatment satisfaction and impact of the bipolar 
disorder on life style. Bipolar disorders 2004;6(6):487-97. 
 (5)  Kennedy A, Reeves D, Bower P, Lee V, Middleton E, Richardson G, et al. The effectiveness 
and cost effectiveness of a national lay-led self care support programme for patients with 
long-term conditions: a pragmatic randomised controlled trial. Journal of Epidemiology 
and Community Health 2007;61(3):254-61. 
 (6)  National Collaborating Centre for Mental Health, National Institute for Clinical Excellence. 
Bipolar disorder: The management of bipolar disorder in adults, children, and young 
people in primary and secondary care - CG38.  National Institute for Clinical Excellence; 
2006.  
 (7)  Veterans Administration and Department of Defense. VA/DoD clinical practice guideline 
for management of bipolar disorder in adults. Version 2.0 ed. Washington DC: Veterans 
Administration; 2010. 
 (8)  Colom F, Vieta E. Psychoeducation manual for bipolar disorder. Cambridge University 
Press; 2006. 
 (9)  Colom F, Vieta E, Sanchez-Moreno J, Palomino-Otiniano R, Reinares M, Goikolea JM, et al. 
Group psychoeducation for stabilised bipolar disorders: 5-year outcome of a randomised 
clinical trial. The British Journal of Psychiatry 2009;194(3):260-5. 
 (10)  Colom F, Vieta E, Martinez-Aran A, Reinares M, Goikolea JM, Benabarre A, et al. A 
randomized trial on the efficacy of group psychoeducation in the prophylaxis of 
recurrences in bipolar patients whose disease is in remission. Archives of general 
psychiatry 2003;60(4):402-7. 
 (11)  Colom F, Vieta E, Reinares M, Martinez-Aran A, Torrent C, Goikolea JM, et al. 
Psychoeducation efficacy in bipolar disorders: beyond compliance enhancement. The 
Journal of clinical psychiatry 2003;64(9):1101. 
 (12)  Bond K, Anderson IM. Psychoeducation for relapse prevention in bipolar disorder: a 
systematic review of efficacy in randomized controlled trials. Bipolar disorders 2015. 
 (13)  Dunn C, Makin N. Clinical Audit Report: Bipolar Disorder (CG185).  Lancashire Care 
Foundation Trust; 2015.  
27 
 
 (14)  Morriss R, Lobban F, Riste L, Davies L, Holland F, Long R, et al. Clinical effectiveness and 
acceptability of structured group psychoeducation versus optimised unstructured peer 
support for patients with remitted bipolar disorder (PARADES): a pragmatic, multicentre, 
observer-blind, randomised controlled superiority trial. The Lancet Psychiatry 2016. 
 (15)  Morriss RK, Lobban F, Jones S, Riste L, Peters S, Roberts C, et al. Pragmatic randomised 
controlled trial of group psychoeducation versus group support in the maintenance of 
bipolar disorder. BMC psychiatry 2011;11(1):114. 
 (16)  Dolan P, Gudex C, Kind P, Williams A. The time trade-off method: Results from a general 
population study. Health economics 1996;5(2):141-54. 
 (17)  The EuroQol Group. EuroQol-a new facility for the measurement of health-related quality 
of life. Health policy 1990;16(3):199-208. 
 (18)  National Institute for Clinical Excellence. Guide to the Methods of Technology Appraisal.  
National Institute for Clinical Excellence; 2013.  
 (19)  Davies LM, Lewis S, Jones PB, Barnes TR, Gaughran F, Hayhurst K, et al. Cost-effectiveness 
of first-v. second-generation antipsychotic drugs: results from a randomised controlled 
trial in schizophrenia responding poorly to previous therapy. The British journal of 
psychiatry: the journal of mental science 2007;191:14-22. 
 (20)  Davies LM, Barnes TR, Jones PB, Lewis S, Gaughran F, Hayhurst K, et al. A Randomized 
Controlled Trial of the Cost-Utility of SecondGeneration Antipsychotics in People with 
Psychosis and Eligible for Clozapine. Value in Health 2008;11(4):549-62. 
 (21)  Hayhurst H, Palmer S, Abbott R, Johnson T, Scott J. Measuring health-related quality of life 
in bipolar disorder: relationship of the EuroQol (EQ-5D) to condition-specific measures. 
Quality of life research 2006;15(7):1271-80. 
 (22)  Keller MB, Lavori PW, Friedman B, Nielsen E, Endicott J, Donald-Scott P, et al. The 
Longitudinal Interval Follow-up Evaluation: a comprehensive method for assessing 
outcome in prospective longitudinal studies. Archives of general psychiatry 
1987;44(6):540-8. 
 (23)  Scott JAN, Paykel E, Morriss R, Bentall R, Kinderman P, Johnson T, et al. Cognitive-
behavioural therapy for severe and recurrent bipolar disorders. The British Journal of 
Psychiatry 2006;188(4):313-20. 
 (24)  Lobban F, Taylor L, Chandler C, Tyler E, Kinderman P, Kolamunnage-Dona R, et al. 
Enhanced relapse prevention for bipolar disorder by community mental health teams: 
cluster feasibility randomised trial. The British Journal of Psychiatry 2010;196(1):59-63. 
 (25)  Curtis L. The Unit Costs of Health and Social Care 2012. Kent: Personal Social Services 
Research Unit; 2013.  
 (26)  Chisholm D, Knapp MRJ, Knudsen HC, Amaddeo F, Gaite LUIS, Van Wijngaarden BOB. 
Client Socio-Demographic and Service Receipt Inventory-European Version: development 
of an instrument for international research. The British Journal of Psychiatry 
2000;177(39):s28-s33. 
28 
 
 (27)  Beecham J, Knapp M. Costing psychiatric interventions. Gaskell In Measuring Mental 
Health Needs. Edited by Thornicroft G. London; 2001. p. 163-83. 
 (28)  Department of Health. National Schedule of Reference Costs 2012-2013.  Department of 
Health; 2013.  
 (29)  Faria R, Gomes M, Epstein D, White IR. A guide to handling missing data in cost-
effectiveness analysis conducted within randomised controlled trials. Pharmacoeconomics 
2014;32(12):1157-70. 
 (30)  Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the 
economic evaluation of health care programmes: Oxford University Press. New York 2005. 
 (31)  Briggs MA, Sculpher M. An introduction to Markov modelling for economic evaluation. 
Pharmacoeconomics 1998;13(4):397-409. 
 (32)  Graham JW, Olchowski AE, Gilreath TD. How many imputations are really needed? Some 
practical clarifications of multiple imputation theory. Prevention Science 2007;8(3):206-13. 
 (33)  White IR, Royston P, Wood AM. Multiple imputation using chained equations: issues and 
guidance for practice. Statistics in medicine 2011;30(4):377-99. 
 
 
